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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not aspirin
is effective in helping to prevent breast cancer in women ages 45 years and older.
STUDY DESIGN: Review of three English language primary studies published in 2005, 2007,
and 2008
DATA SOURCES: Two randomized, double blind, placebo controlled clinical trials and one
prospective, population based cohort study comparing aspirin to placebo were found using
PubMed and Cochrane databases.
OUTCOMES MEASURED: Breast cancer development was measured in several ways. Tumor
characteristics were measured at diagnosis, including size, metastasis to lymph nodes, histology
of the mass, histology differentiation, and estrogen and progesterone status. Outcomes were also
measured by pathology reports, cytology reports, on strong clinical and radiologic or laboratory
marker evidence, and also self reported questionnaire.
RESULTS: The two randomized controlled trials showed that the use of aspirin has no
significant effect on the prevention of breast cancer. The cohort study showed an inverse
relationship between the use of aspirin and the risk of cancer incidence and mortality.
CONCLUSIONS: Although the two RCTs showed no effect of aspirin on the prevention of
breast cancer, the cohort study showed some promise in the use of aspirin and breast cancer
prevention. The dose of aspirin used in the RCTs was only 100mg, and the doses in the cohort
study varied based on individual reporting. Increasing the dose of aspirin to 325mg in future
studies may show some effect in the prevention of breast cancer.
KEY WORDS: Aspirin, Breast Cancer
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INTRODUCTION
Breast cancer is defined as “a malignant proliferation of epithelial cells lining the ducts or
lobules of the breast”, resulting from a single cell that undergoes acquired or germ-line mutations,
and eventually expresses “full malignant potential”.1 After skin cancer, breast cancer is the most
commonly diagnosed cancer in U.S. women, with death rates higher than for any other cancer,
besides lung cancer. Mortality has decreased slightly due to early detection methods; however
prevention of the disorder could further lower mortality. One in eight women in the United States
will develop breast cancer during her lifetime. About 85% of breast cancer cases occur in women
with no prior family history of breast cancer. In 2011, “230,480 new cases of invasive breast
cancer were expected to be diagnosed in women in the U.S.”, with “57,650 new cases of noninvasive (in situ) breast cancer”, and “39,520 women in the U.S. were expected to die in 2011
from breast cancer”.2 The national expenditure for breast cancer care in 2006 was $13.886
billion.3
The biggest risk factor for the “development of breast cancer is age”, with the median age
of diagnosis of 61 years, though many women with breast cancer do not have any “identifiable
risk factors”. 4 The initial discovery of breast cancer in about 70% of patients is a lump in the
breast that is “single, non-tender” and “firm to hard with ill-defined margins”4. Mammography is
useful in that it detects masses before they can be palpated, sometimes even 2 years prior to
being felt in the case of slow growing cancers. The most common method of treating breast
cancer is surgical resection which can be breast conserving or a full mastectomy. Other treatment
methods include chemotherapy, radiation therapy and hormone therapy such as ERDs, SERMs
and aromatase inhibitors.4
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Evidence has shown that aspirin might be effective in the prevention of breast cancer, so
that women will not have to undergo such invasive measures to treat breast cancer in the future.
NSAIDS have been shown to “suppress tumor growth” in “experimental animal models”5.
Observational epidemiological studies have suggested a strong inverse association, with risk
reduction 20-50% for various sites in several different cancer types, including breast cancer.
Aspirin is thought to reduce cancer risk through its effect on cyclooxygenase (COX). Aspirin
inhibits COX enzymes, particularly COX 2 which is “linked to inflammation and tumor growth”,
effecting “apoptosis, cell migration and angiogenesis”5. There is also a possible role of aspirin as
an antioxidant and in the “modulation of estrogen biosynthesis”.5
OBJECTIVE
The objective of this selective EBM review is to determine whether or not aspirin is
effective in helping to prevent breast cancer in women ages 45 years and older.
METHODS
The criteria for selection of studies included women ages 45 years and older. The
intervention used was aspirin use. The types of studies included consist of two randomized
control trials (RCT) and a prospective, population based cohort study. In each RCT, results are
compared between the groups taking aspirin and the placebo group. The cohort study compares
groups taking aspirin to those not taking medication6. The outcomes measured are breast cancer
incidence and mortality.
Articles were found via Pubmed and Cochrane. The key words used in searches were
“aspirin” and “breast cancer”. All articles are written in English and were published in peer
reviewed journals. Articles were selected based on their relevance and on the importance of
outcomes of the patient or POEMs. Inclusion criteria consisted of articles using aspirin as an
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intervention, female participants aged 45 years and older, and studies that were randomized
controlled trials. Exclusion included any observational studies prior to 2005 because of an
already existing non-Cochrane meta-analysis. The statistics reported of use include
Relative Risk (RR), 95% Confidence Interval (CI), Relative Risk Reduction (RRR), Absolute
Risk Reduction (ARR), Numbers Need to Treat (NNT), and p-value. Table 1 includes the
demographics of the included studies.
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Table 1: Table of Demographics and Characteristics of included studies
Study Type
# Pts
Age Inclusion
Exclusion
W/D
(yrs) criteria
criteria
Bardia, Prospective, 22507 55Postmenopausal Premenopausal, 0
20076 population
69
women
cancer other than
based
nonmelanoma
cohort study
cancer, receiving
chemotherapy
through 1992,
history of heart
disease through
1992, died
between 1986
and 1992, did
not complete
1992
questionnaire
Cook, RCT
39,876 45
No history of
History of
0
5
2005
years cancer or
adverse effects
and
cardiovascular
to aspirin; taking
older disease or other aspirin or
major chronic
NSAIDs more
illness
than once a
week; taking
anticoagulants or
corticosteroids;
taking vitamin
A, vitamin E or
beta carotene
more than once a
week
Zhang, Double
39,876 45
No history of
History of
0
20087 blind, RCT
years cancer or
adverse effects
and
cardiovascular
to aspirin; taking
older disease or other aspirin or
major chronic
NSAIDs more
illness
than once a
week; taking
anticoagulants or
corticosteroids;
taking vitamin
A, vitamin E or
beta carotene
more than once a
week

Intervention
s
Self
reported
aspirin or
NSAID
intake

Low dose
aspirin, 100
mg
administere
d every
other day
for 10 years

Low dose
aspirin, 100
mg
administere
d every
other day
for 10 years
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OUTCOMES MEASURED
All outcomes measured were based on relevance to Patient Oriented Evidence that
Matters (POEMS). Zhang et. al. measured outcomes based on “tumor characteristics at
diagnosis”, including size, metastasis to lymph nodes, histology of the mass, histologic
differentiation, estrogen and progesterone receptor status7. Cook et. al. measured outcomes based
on pathology reports, cytology reports and on “strong clinical and radiological or laboratory
marker evidence”5. For reported cases of breast cancer, medical records and other relevant
information was sought and reviewed by physicians blinded to the treatment5. Lastly Bardia et. al.
measured outcomes based on self reported questionnaire, with cancer incidence and mortality
ascertained by annual linkage to the “Iowa Surveillance, Epidemiology and End Results Cancer
Registry and death certificates”6.
RESULTS
Bardia et. al. determined the effects of aspirin on breast cancer through a prospective,
population based cohort study, in which participants were analyzed via their returned
questionnaires. The study found that during 10 years of follow up, “3487 cases of cancer were
observed”, with an “inverse trend for cancer risk with frequency of aspirin use (Ptrend<0.001)”
observed6. The use of aspirin was inversely associated with cancer incidence, as seen in table 2.
Table 2: Relative Risk and 95% Confidence Interval for Incidence of Breast Cancer in
Those Taking Aspirin
Bardia et. al. 2007
Aspirin Use per week RR 95% CI
Never
1.00 Referent
Ever
0.84 0.80 to 0.93
≤1
0.85 0.70 to 0.93
2-5
0.83 0.77 to 0.94
≥6
0.81 0.80 to 0.98
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Bardia et. al. found a “weak inverse association between the frequency of aspirin use and
cancer mortality”, with aspirin ever use “inversely associated with cancer mortality (RR = 0.87,
95% CI = 0.76 to 0.99)”, as seen in table 3.6
Table 3: 95% Confidence Interval for Incidence and Mortality of Breast Cancer in Those
Taking Aspirin
Bardia et. al. 2007
Aspirin Use per week RR 95% CI
Never
1.00 Referent
Ever
0.87 0.76 to 0.99
≤1
0.91 0.78 to 1.06
2-5
0.83 0.69 to 1.00
≥6
0.82 0.68 to 0.99
Bardia et. al. excluded women who were premenopausal, had cancer or who were
receiving chemotherapy since these groups would alter the incidence of breast cancer and would
make it difficult to determine if aspirin had an effect. The study observed differences in smokers
versus nonsmokers. The “inverse association between aspirin use and breast cancer mortality
was evident among never smokers (for aspirin use six or more times per week versus never use,
95% CI = 0.61 to 0.99) and suggestive among former smokers (for aspirin use six or more times
per week versus never use, 95% CI = 0.51 to 1.24) but not among current smokers (for aspirin
use six or more times per week versus never use, 95% CI = 0.63 to 1.46)”6. The study also
looked at the effect of NSAIDs and the risk of cardiovascular incidences with both aspirin and
NSAIDs.
Zhang et. al. looked at cases of total, invasive and in situ breast cancer, finding no
significant effect on risk with low dose aspirin according to tumor size, histology and estrogen or
progesterone receptor status. Total cases of breast cancer with aspirin treatment was “762 cases”,
while the total cases with placebo treatment was “779 cases”, with a “95% CI of 0.88 – 1.08”7.
Cases of in situ breast cancer with aspirin treatment was “159 cases”, while the cases of in situ
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cancer with placebo treatment was “165 cases”, with a “95% CI of 0.78 to 1.20”7. Cases of
invasive breast cancer with aspirin treatment was “608 cases”, while the cases of invasive cancer
with placebo treatment was “622 cases”, with a “95% CI of 0.87 to 1.09” as seen in table 47.
“Morbidity and mortality follow-up were 97.2% and 99.4%” respectively (deaths were reported
by “family members, postal authorities, and a search of the National Death Index”) 7. The
number needed to treat (NNT) was -1429, meaning that for every 1429 participants who took
prophylactic aspirin, there was one fewer incidence of breast cancer than in the group of
participants taking placebo.
Table 4: Cases of Breast Cancer According to Randomized Aspirin Treatment

Total Breast
Cancer
In situ Breast
cancer
Invasive Breast
cancer

Zhang et. al. 2008
Number of cases with
Number of cases with
Aspirin (n=19934)
placebo (n=19942)
762
779

Hazards
Ratio
0.98

159

165

0.96

608

622

0.98

95% CI
0.88 –
1.08
0.78 1.20
0.871.09

Cook et. al. found after 10 years of follow up, there were “1230” cases of invasive breast
cancer, with “1535” cases of in situ breast cancer5. There was no effect of aspirin on the
incidence of breast cancer with the “95% CI of 0.87 to 1.09 and p= 0.68”5. Table 5 shows that
there is no increase in the effect of aspirin over duration of time.
Table 5: Cumulative Effect of Aspirin on Breast Cancer Prevention over Time
Cook et. al. 2005
Follow up time
95% CI
P
2 years
0.87 – 1.09
0.74
5 years
0.83 – 1.12
0.63

Cook et. al. also compared the incidence of breast cancer in smokers and nonsmokers.
“Among never smokers, women assigned to aspirin had an increased risk (95% CI = 0.94 – 1.30,
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p=0.21), but among past smokers they had a decreased risk (95% CI = 0.94 – 1.30, p=0.07), with
no effect among current smokers (95% CI = 0.69-1.25, p= 0.63)”5. The study took into account
compliance of participants as well. There were no effects on breast cancer in women at the time
they stopped taking “at least two thirds of their study pills”5. “Among women who consistently
took at least two thirds of their study aspirin or placebo during the first 2 years”, there was no
effect on breast cancers occurring after 2 years of follow up “(95% CI = 0.87 – 1.13 and p =
0.88)”, and “the same was true among women who complied with study medication use during
the first 5 years of intervention”5. The study also looked into the effect of aspirin on several other
types of cancers. The NNT in this RCT was -1429.
DISCUSSION
The two RCTs used aspirin at dosages of 100 mg every other day while the prospective
cohort study asked participants to report only how regularly they took aspirin and not the amount.
Taking higher doses of aspirin more regularly might provide some benefits.
Aspirin is widely available and convenient for patients in that it is over the counter.
Contraindications to use include hypersensitivity to salicylates or other NSAIDs, asthma, rhinitis,
nasal polyps, inherited or acquired bleeding disorders or pregnancy. Adverse effects include
salicylate sensitivity, tinnitus, and upper gastrointestinal events.8
Limitations existed in the articles included in this paper. In all of the studies, patients
were responsible for taking medication and reporting how compliant they were. The studies were
not performed in in-patient settings where they could be monitored because they persisted for a
decade. There is some variability in the results in that some patients might not have been
accurate in recording how much medication they took. The cohort study was not performed as a

Quartuccio, Aspirin and Breast Cancer 9
double blind RCT, but instead participants filled out questionnaires about the medications they
took and how often.
There were limitations in searching for articles as well. There are an abundance of cohort
studies but few RCTs on the topic at hand. RCTs are more useful in that that they typically
perform studies in a double blind fashion, which eliminates bias.
CONCLUSION
According to the two RCTs, aspirin is not effective in preventing breast cancer in women
ages 45 years and older. The prospective cohort study however did show aspirin to be effective
in preventing breast cancer in women ages 45 years and older. The issue at hand comes down to
dosage. Participants who received aspirin in the RCTs took 100mg every other day of aspirin. In
the cohort study, participants recorded how often they took aspirin, which could have ranged in
value with some even taking 325mg (the study does not state the amounts). Cook et. al. states
that low dose aspirin appears “relatively specific for COX-1”, though “higher doses inhibit both
COX-1 and COX-2 and may have a stronger anti-inflammatory effect”5. “COX-2 expression” is
“increased in breast cancer tumor tissue”, which suggests that “higher doses of aspirin may be
more effective in cancer prevention”5.
Future study is warranted to determine if higher dosages of aspirin at closer intervals is
more effective than 100 mg of aspirin every other day7. The most effective way to determine
this is by a double blind RCT comparing the higher and lower dosages of aspirin against a
placebo.
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